2013
DOI: 10.4103/2278-0513.119257
|View full text |Cite
|
Sign up to set email alerts
|

Targeted therapy for metastatic renal cell carcinoma: Current treatment and future directions

Abstract: Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 3% of all adult cancers. The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being a predominantly cytokine-based treatment to the use of targeted agents, which include Sorafenib, Sunitinib, Bevacizumab, Temsirolimus, Everolimus, Pazopanib, Axitinib, and most recently Tivozanib. Despite these advances mRCC remains a major health problem. Additional studies are needed to optimize the use of these agents in b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…The RCC frequency in men is 1.5-2.0 times greater than in woman, with an age peak around 60-70 years ( 5 ). The exact RCC etiology remains unclear, although lifestyle risk factors such as cigarette smoking and obesity, and iatrogenic factors like hypertension, use of antihypertensive medications and acquired renal cystic disease have been identified as potential risk factors ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…The RCC frequency in men is 1.5-2.0 times greater than in woman, with an age peak around 60-70 years ( 5 ). The exact RCC etiology remains unclear, although lifestyle risk factors such as cigarette smoking and obesity, and iatrogenic factors like hypertension, use of antihypertensive medications and acquired renal cystic disease have been identified as potential risk factors ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%